assessment report - ema.europa.eu€¦ · assessment report ema/396618/2018 page 6/131 . 1....

Download Assessment report - ema.europa.eu€¦ · Assessment report EMA/396618/2018 Page 6/131 . 1. Background information on the procedure . 1.1. Type II variation . Pursuant to Article

If you can't read please download the document

Upload: others

Post on 15-Nov-2019

2 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

OCALIVA, INN-obeticholic acid - ema.europa.eu · Assessment report EMA/725757/2016 Page 7/129 1. Background information on the procedure 1.1. Submission of the dossier The applicant

Assessment report - ema.europa.eu€¦ · Assessment report EMA/789531/2016 Page 7/164 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Crohn’s disease

Assessment report on Rubus idaeus L., folium - ema.europa.eu · 28 January 2014 . EMA/HMPC/44209/2012 Corr. 1. Committee on Herbal Medicinal Products (HMPC) Assessment report on

Withdrawal Assessment report - ema.europa.eu · Withdrawal Assessment rep ort EMA/CHMP/52035/2017 Page 5/43 2. Scientific discussion 2.1. Introduction Hypercalcemia of malignancy

Macular Edema - ema.europa.eu · EU Regulatory Workshop – Ophthalmology EMA, London, UK 27-28 October 2011 Macular Edema 1. Definition – Classification 2. Frequency – Morbidity

Assessment report - ema.europa.eu€¦ · Assessment report . Sarclisa . International non-proprietary name: isatuximab . Procedure No. EMEA/H/C/004977/0000 . Note Assessment report

Assessment report - ema.europa.eu · EMA/CHMP/434726/2018 Page 6/98 . GGT gamma-glutamyltransferase . GvHD graft versus host disease . HAMA human antimurine antibodies . HiDAC high-dose

Assessment report - ema.europa.eu · Assessment report EMA/206826/2019 Page 5/71 1. Background information on the procedure 1.1. Type II variation Pursuant to Article 16 of Commission

Assessment report - ema.europa.eu · Assessment report EMA/CHMP/750187/2017 Page 5/115 . DMARD Disease modifying antirheumatic drug DNA Deoxyribonucleic Acid DSC Differential Scanning

Assessment report - ema.europa.eu · Note . Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/41918/2019

Jinarc II-09 - EPAR - ema.europa.eu · Assessment report EMA/508732/2018 Page 3/34 1. Background information on the procedure 1.1. Type II variation Pursuant to Article 16 of Commission

Assessment report - ema.europa.eu€¦ · Assessment report EMA/486136/2016 Page 5/50 1. Background information on the procedure 1.1. Submission of the dossier The applicant Teva

Assessment report Talzenna - ema.europa.eu · Repro duction is authorised provided the source is acknowledged. 26 April 2019 . EMA/270498/2019 . Committee for Medicinal Products for

CHMP assessment report - ema.europa.eu · 20 February 2014 . EMA/CHMP/175692/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . DuoResp Spiromax

PA Damage Assessment Field Guide Damage Assessment...County EMA as soon as possible. Your County EMA will provide it to the Ohio EMA. Damage Assessment is a continuous process. The

Assessment EMA - Offer by Netherlands - Amsterdam metropolitan · Assessment EMA - Offer by Netherlands - Amsterdam metropolitan ... The offer indicates the proposed permanent premises,

Assessment report - ema.europa.eu · Assessment report EMA/CHMP/222019/2015 Page 7/122 . UC Ultracentrifugation . ULN upper limit of normal . V volume of distribution . VAS visual

Assessment report - ema.europa.eu · Assessment report EMA/703393/2018 Page 6/79 1. Background information on the procedure 1.1. Submission of the dossier The applicant Cinfa Biotech

Assessment report - ema.europa.eu · Assessment report EMA/608624/2019 Page 4/201 Classified as public by the European Medicines Agency . List of abbreviations . ACR American College

CHMP ASSESSMENT REPORT Myfenax - ema.europa.eu

Annual report 2017 - ema.europa.eu · 1 EMA – Annual Report 2017 Table of contents Mission statement 2 Foreword by Christa Wirthumer-Hoche, Chair of EMA Management Board 4 Introduction

Assessment report - ema.europa.eu · Assessment report EMA/CHMP/726758/2015 Page 7/74 2. Scientific discussion 2.1. Introduction Chronic lymphocytic leukaemia (CLL) is a progressive

Assessment report - ema.europa.eu...Assessment report EMA/130014/2017 Page 3/35 1. Background information on the procedure 1.1. Type II variation Pursuant to Article 16 of Commission

EMA Assessment Report May 2014

Assessment report - ema.europa.eu · Assessment report BESPONSA International non-proprietary name: inotuzumab ozogamicin Procedure No. EMEA/H/C/004119/0000 Note Assessment report

Assessment report - ema.europa.eu · Assessment report EMA/545605/2015 Page 4/63 1. Background information on the procedure 1.1. Type II variation Pursuant to Article 16 of Commission

EMA Procedural advice for users of the centralised ... · [email protected]. Send all queries regarding the Web functionality to: EMAwebservices. EMA Procedural advice for users

PSUR Submissions in Single Assessment via EMA …esubmission.ema.europa.eu/gateway/eSubmissions of PSUR via EMA... · PSUR Submissions in Single Assessment via EMA Gateway Webclient

Assessment report - ema.europa.eu€¦ · RMC Risk Management Committee . RMP Risk management plan . RR Relative Risk . RVT Retinal vein thrombosis . Assessment report EMA/CHMP/383987/2014

Assessment report - ema.europa.eu...Assessment report EMA/169793/2017 Page 10/59 Among subjects with pharmacokinetic data in Age Group 2, 13 of 17 received the emtricitabine solution

CHMP assessment report 15 October 2020 EMA/584450/2020

CHMP assessment report - ema.europa.eu · The application was received by the EMA on 26 February 2010. The procedure started on 24 March 2010. The Rapporteur's first Assessment Report

Assessment report - ema.europa.eu · Assessment report EMA/650359/2016 Page 4/47 1. Background information on the procedure 1.1. Submission of the dossier The applicant Sigma-tau

Assessment report - ema.europa.eu · Assessment report EMA/199991/2020 Page 4/103 List of abbreviations . ADA Anti-drug antibodies . ADR Adverse drug reaction . AE Adverse event

9 October 2014 EMA/686022/2014 Pharmacovigilance Risk ... · 9 October 2014 . EMA/686022/2014 . Pharmacovigilance Risk Assessment Committee (PRAC) Assessment report . Procedure under